Navigation Links
Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit
Date:8/4/2010

JUPITER, Fla., Aug. 4 /PRNewswire-FirstCall/ -- Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic") announced today that the United States District Court for the Southern District of Florida has approved the final resolution of the consolidated stockholder class action lawsuit, Miller v. Dyadic International, Inc. et al, and dismissed the lawsuit with prejudice.

(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20091214/DYADICLOGO )

The lawsuit initially filed in October 2007 asserted class action claims under federal securities laws based on allegations of misstatements and omissions by Dyadic and certain of its current and former officers and directors arising out of alleged improprieties at Dyadic's Asian subsidiaries.  As reported in Dyadic's latest consolidated financial statements, Dyadic established a cash reserve in connection with the class action lawsuit which adequately covers the costs associated with resolving this matter.

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "We are pleased to put this matter behind us so we can continue focusing on growing our business through the ongoing sale of enzymes and the monetization of our C1 platform technology through potential licensing arrangements and other collaborations."

About Dyadic

Dyadic is a global biotechnology company that uses its patented and proprietary technologies for the discovery, development, manufacture and sale of enzyme products and solutions to address the needs of the bioenergy, biopharmaceutical and industrial enzyme markets. Please visit Dyadic's website at www.dyadic.com

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International Engages The Abraham Group as Strategic Advisor
2. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
3. Dyadic International Strengthens Management Team
4. Dyadic International Extends Collaboration With The Scripps Research Institute
5. Renhuang Receives AAA(1) Rating from Chinese Academy of International Trade & Economic Cooperation of Ministry of Commerce
6. SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents
7. FRC Systems International State-of-the-art Industrial Wastewater Treatment Systems
8. Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition
9. Bacterin International Appoints Three New Members to Its Board of Directors
10. THE PLANNING SHOP international Announces Oncology Business Unit
11. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics (OTCQB: ... personalized immune therapies for solid tumor cancers, today ... million financing it announced last Friday, March 17, ... several institutional investors securities totaling 28,843,692 shares, comprised ... and 10,000,000 shares of Class C Warrants pre-funded ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
(Date:3/23/2017)... New Orleans, La. (PRWEB) , ... March 23, ... ... of real-time, industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” ... for APMT customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s ...
(Date:3/22/2017)... Good Start Genetics, a leading family genomics ... million covered lives mark through its most recent payor ... . With newly signed contracts nationally and others ... payor acceptance based on the quality of its science, ... its industry-leading customer care and support and its published ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela ... The Chancellor came to the DERMALOG stand together with the Japanese Prime ... partner country. At the largest German biometrics company the two government leaders ... iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
Breaking Biology News(10 mins):